Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 16, 2017. The document serves as a transaction notification reporting changes in the notional interest of Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions relate to the re-investment of dividends paid on January 12, 2017, under the Company's 2009 Performance Share Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company. It exclusively details specific share transactions for individual executives.
| Instrument | Transaction Date | Transaction Price | Total Aggregated Volume (Shares) |
|---|---|---|---|
| Ordinary Shares (25p each) | January 12, 2017 | £15.66 | 54,318.075 |
Note: The total aggregated volume represents the sum of shares acquired by all listed PDMRs through dividend re-investment.
Material Changes
The filing reports an increase in the notional interest of Ordinary Shares for eleven senior executives. These changes are mechanical results of dividend re-investment plans and do not represent open market purchases or sales by the executives. No material changes to the Company's financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of executive share plan activity.
Important Facts for Investors
- Transaction Nature: All reported transactions are increases in notional share interest resulting from the automatic re-investment of dividends, not discretionary trading.
- Key Personnel: Transactions were reported for the CEO (Sir Andrew Witty), CEO Designate (Ms E Walmsley), CFO (Mr S Dingemans), and eight other senior officers.
- Share Price: The re-investment price for all transactions was £15.66 per share.
- Financial Data: This document does not provide GSK's quarterly or annual financial performance data; investors should refer to Form 20-F or earnings releases for those metrics.